Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences Inc (NERV) is a clinical-stage biopharmaceutical company pioneering therapies for central nervous system disorders. This dedicated news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's trajectory in neuroscience innovation.
Discover comprehensive coverage of NERV's press releases including trial results for schizophrenia and Parkinson's disease candidates, partnership announcements with global pharmaceutical leaders, and progress reports on its insomnia/depression therapeutic programs. The page serves as a vital resource for tracking FDA interactions, licensing agreements, and research breakthroughs.
All content is curated to meet investor needs for accurate, up-to-date information while maintaining compliance with financial disclosure standards. Users benefit from consolidated access to essential updates without promotional bias, supported by Minerva's established collaborations with entities like Mitsubishi Tanabe Pharma.
Bookmark this page for streamlined monitoring of NERV's advancements in CNS drug development. Check regularly for new developments impacting the company's position in the competitive biopharma landscape.
Minerva Neurosciences (Nasdaq: NERV) reported its Q4 and fiscal year 2024 financial results. The company continues to address questions raised in the FDA's Complete Response Letter (CRL) for roluperidone, its treatment for negative symptoms in schizophrenia patients.
Financial highlights include: R&D expenses decreased to $2.0 million for Q4 2024 (vs $4.7 million in Q4 2023) and $11.9 million for full-year 2024 (vs $12.7 million in 2023). G&A expenses remained at $2.5 million for Q4 2024 and decreased to $9.9 million for full-year 2024 (vs $10.4 million in 2023).
The company reported a Q4 2024 net loss of $4.3 million ($0.56 per share) compared to a $9.0 million loss ($1.19 per share) in Q4 2023. For the full year 2024, Minerva reported net income of $1.4 million ($0.19 per share) versus a net loss of $30.0 million ($4.61 per share) in 2023. Cash position stood at $21.5 million as of December 31, 2024, down from $41.0 million a year earlier.
Minerva Neurosciences (NERV) reported Q3 2024 financial results with notable changes in expenses and income. R&D expenses decreased to $1.9 million from $3.4 million in Q3 2023, while G&A expenses slightly decreased to $2.5 million from $2.6 million. The company reported net income of $22.5 million for Q3 2024, compared to a net loss of $7.8 million in Q3 2023. Cash position stood at $26.6 million as of September 30, 2024. The FDA previously issued a Complete Response Letter for roluperidone's NDA for treating negative symptoms in schizophrenia patients, and the company continues interactions with the FDA to address raised questions.
Minerva Neurosciences (Nasdaq: NERV) reported its Q2 2024 financial results and business updates. Key highlights include:
1. The FDA issued a Complete Response Letter (CRL) for roluperidone's NDA for treating negative symptoms in schizophrenia patients.
2. R&D expenses increased to $3.9 million in Q2 2024 from $1.9 million in Q2 2023.
3. G&A expenses decreased to $2.4 million in Q2 2024 from $2.6 million in Q2 2023.
4. Net loss for Q2 2024 was $8.2 million ($1.09 per share) compared to $6.2 million ($1.12 per share) in Q2 2023.
5. Cash position as of June 30, 2024, was $31.0 million, down from $41.0 million on December 31, 2023.
Minerva Neurosciences, Inc. reported its first-quarter 2024 financial results, including an update on the roluperidone NDA and completion of a Phase 1b clinical trial for patients with schizophrenia. The company's R&D expenses increased due to FDA review costs, while G&A expenses decreased. The net loss for the quarter was $8.6 million. Cash position decreased to $34.9 million.
FAQ
What is the current stock price of Minerva Neurosci (NERV)?
What is the market cap of Minerva Neurosci (NERV)?
